Want to see HK:2137 full AI Analyst Report?
2137 Stock Chart & Stats
HK$1.44
HK$0.04(3.74%)
At close: 4:00 PM EST
HK$1.44
HK$0.04(3.74%)
Day’s Range― - ―
52-Week RangeHK$0.90 - HK$2.54
Previous CloseN/A
Volume2.92M
Average Volume (3M)6.36M
Market Cap
HK$678.54M
Enterprise Value-HK$1.19K
Total Cash (Recent Filing)HK$1.94B
Total Debt (Recent Filing)HK$8.93M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,577,100
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low leverage profile and minimal debt relative to equity materially reduce refinancing and solvency risk for a development-stage biotech. This provides durable financial flexibility to sustain R&D and regulatory programs, supports partnership negotiations, and lowers the likelihood of distress-driven dilution over the next 2–6 months.
Equity Cushion (2021–2025)Sustained positive equity across multiple years offers a tangible capital buffer to absorb ongoing losses and fund clinical progress without immediate insolvency risk. That cushion supports continuity of operations and allows management to prioritize development milestones and partnerships rather than emergency capital raises in the medium term.
Focused Pipeline & Collaborative Commercial StrategyA business model centered on advancing infectious-disease therapies, plus explicit use of collaborations for commercialization, is structurally advantageous: it spreads development and go-to-market risk, leverages partner capabilities, and creates multiple potential revenue paths as candidates progress through approval and launch phases.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate the company is reliant on external funding or existing liquidity to sustain operations. Over a multi-month horizon this elevates financing risk, may force dilutive raises or partnership concessions, and constrains ability to scale commercial activities if clinical timelines slip.
Sustained Losses & Negative MarginsDeep negative margins and recurring net losses reflect an absence of operating profitability and limited margin sustainability. Coupled with a sharp revenue contraction, this weakens the path to self-sustaining cash generation and increases dependence on financing or partner commercialization to achieve scale over the next several quarters.
Historical Capital Strain / VolatilityA prior episode of negative equity signals material past capital erosion, which raises the bar for management to rebuild investor confidence and maintain liquidity. In a sector where clinical setbacks or funding gaps can be binary, this history underscores structural vulnerability to adverse events and funding-market volatility.
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$0.90 and its highest was HK$2.54 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$678.54M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 11 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -HK$0.035 earnings per share for the quarter, beating the consensus estimate of -HK$0.07 by HK$0.035.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate is -0.13.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,577,100 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.035 in its last earnings report, beating expectations of -HK$0.07. Following the earnings report the stock price went down -3.947%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―